IRIDEX Corporation — Q2 2023 Form 10-Q
Business context and reporting period. IRIDEX develops, manufactures, and markets ophthalmic laser systems, delivery devices, and consumables used to treat glaucoma and retinal diseases. The quarter ended July 1, 2023 and comprised 13 weeks; the six-month period also ended July 1, 2023. Comparatives are the periods ended July 2, 2022. Amounts below are USD millions unless stated otherwise.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $12.855 | $13.755 | $26.561 | $27.142 |
| Gross profit / margin | $5.363 / 41.7% | $6.267 / 45.6% | $11.301 / 42.5% | $12.244 / 45.1% |
| Operating loss | $(2.894) | $(2.160) | $(5.238) | $(4.437) |
| Net loss | $(2.766) | $(2.241) | $(4.856) | $(4.632) |
| Basic and diluted loss per share | $(0.17) | $(0.14) | $(0.30) | $(0.29) |
- Cash flow: Six-month operating cash use was $3.984 million, versus $5.823 million a year earlier. Investing cash use was $0.059 million; financing cash use was $0.026 million. Cash declined $4.101 million to $9.821 million.
- Balance sheet: Working capital was $18.7 million, compared with $23.3 million at December 31, 2022. Total liabilities were $23.489 million and stockholders’ equity was $13.450 million. The filing reports no amount drawn on its revolving credit facility.
- Debt and commitments: IRIDEX had an undrawn facility of up to $8.0 million, with a stated term through December 1, 2023. Purchase commitments were approximately $18.1 million through fiscal 2025, including $14.1 million due within 12 months.
Material changes versus the prior comparable period
- Q2 revenue fell 6.5%; six-month revenue fell 2.1%. In Q2, Retina revenue decreased 8.9%, while Cyclo G6 revenue rose 5.2%. For the six months, Retina decreased 5.1% and Cyclo G6 increased 4.4%.
- Management attributed weaker revenue to deferred purchasing decisions in retina and surgical retina and lower royalties following expiration of licensed patents. It also cited softer demand and longer purchase decision cycles amid macroeconomic concerns and a strong U.S. dollar.
- Gross margin declined 3.9 percentage points in Q2 and 2.6 points for the six-month period. The filing attributes the decline primarily to lower revenue and manufacturing overhead absorbed by lower volume.
- Six-month operating expenses were nearly flat overall: lower R&D and sales and marketing costs were offset by higher general and administrative costs, including legal and personnel expenses. Q2 G&A included approximately $0.2 million in employee separation costs related to headcount reductions and cost-saving measures.
- Cash use from operations improved year over year, primarily because the company reduced purchases of components and subsystems as it worked down inventory, partly offset by lower customer cash receipts.
Outlook, commentary, risks, and unusual items
- Management expects continued operating losses and negative operating cash flows, but stated that existing cash and cash equivalents should meet anticipated needs for at least the next 12 months. The filing provides no numerical revenue or earnings guidance.
- Management noted that capital-equipment purchasing may remain pressured by higher borrowing costs and economic weakness. It also cautioned that additional financing may not be available on acceptable terms, if needed.
- Topcon is a related party, exclusive distributor in certain international regions, and a significant customer: it represented 28% of Q2 revenue and 27% of accounts receivable at July 1, 2023. This creates customer and distribution concentration exposure.
- IRIDEX recorded a $146,000 allowance for credit losses after adopting the expected-credit-loss accounting standard on January 1, 2023; adoption resulted in a $244,000 cumulative adjustment to opening equity. Goodwill of approximately $1.0 million was not impaired in the second-quarter annual test.
- The company had capitalized $1.1 million of implementation costs for a cloud-based ERP system; amortization is expected to begin when the system is ready for use. The company also disclosed that the 2018 voluntary recall of a laser accessory remains pending FDA termination.
- Ordinary-course legal matters were not expected by management to have a material adverse effect. Disclosure controls were assessed as effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether sales recover, particularly in retina, and whether the lower gross margin persists as volumes and product mix change.
- Whether cash burn stays within management’s 12-month liquidity expectation, considering the $9.821 million cash balance, operating losses, and near-term purchase commitments.
- Topcon’s ongoing sales contribution, collections, and performance under the exclusive distribution arrangement.
- The status and potential consequences of the pending FDA recall-termination request, and the timing and total cost of ERP implementation.
- The cash-flow statement reports $26,000 of financing cash use, while the MD&A describes financing cash flow as $26,000 provided; investors should verify this apparent sign inconsistency.